TRANSCENTA-B(06628)

2.200-0.150-6.38%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Transcenta Therapeutics Presents Updated Efficacy Data From the Phase I/Ii Transtar102 Trial of Osemitamab Plus Nivolumab and Capox in First-Line G/Gej Cancer at Esmo Asia
  THOMSON REUTERS · 12-05
  Transcenta Therapeutics Presents Updated Efficacy Data From the Phase I/Ii Transtar102 Trial of Osemitamab Plus Nivolumab and Capox in First-Line G/Gej Cancer at Esmo Asia
- TRANSCENTA-B (06628): Updated Efficacy Data of Osemitamab Triple Therapy for First-Line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma Presented at ESMO Asia
  Stock News · 12-05
  TRANSCENTA-B (06628): Updated Efficacy Data of Osemitamab Triple Therapy for First-Line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma Presented at ESMO Asia
- Transcenta (Stock Code: 6628) Releases Updated Efficacy Data for Osemitamab Combination in First-Line G/GEJ Cancer
  Bulletin Express · 12-05
  Transcenta (Stock Code: 6628) Releases Updated Efficacy Data for Osemitamab Combination in First-Line G/GEJ Cancer
- Transcenta Reports Promising Phase I/II Trial Results for Osemitamab in G/GEJ Cancer
  Reuters · 12-05
  Transcenta Reports Promising Phase I/II Trial Results for Osemitamab in G/GEJ Cancer
- Transcenta (06628) Releases November 2025 Monthly Return on Share Capital and Incentive Schemes
  Bulletin Express · 12-04
  Transcenta (06628) Releases November 2025 Monthly Return on Share Capital and Incentive Schemes
- Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 20,000 Shares at HK$2.5 Each
  Stock News · 11-25
  Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 20,000 Shares at HK$2.5 Each
- TRANSCENTA-B (06628) Grants 200,000 Award Shares and 800,000 Share Options
  Stock News · 11-20
  TRANSCENTA-B (06628) Grants 200,000 Award Shares and 800,000 Share Options
- Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 34,000 Shares at HK$2.86 Each
  Stock News · 11-13
  Chairman Qian Xueming Increases Stake in TRANSCENTA-B (06628) with 34,000 Shares at HK$2.86 Each
- TRANSCENTA-B (06628) Appoints EY as New Auditor
  Stock News · 11-12
  TRANSCENTA-B (06628) Appoints EY as New Auditor
- Transcenta Replaces Deloitte With EY Over Audit Fee Dispute
  Reuters · 11-12
  Transcenta Replaces Deloitte With EY Over Audit Fee Dispute
- HK Stock Movement | TRANSCENTA-B (06628) Rises Over 4% as Ozekibart to Submit U.S. Indication Application by Mid-2026
  Stock News · 10-31
  HK Stock Movement | TRANSCENTA-B (06628) Rises Over 4% as Ozekibart to Submit U.S. Indication Application by Mid-2026
- TRANSCENTA-B (06628) Partner Inhibrx Reports Positive Phase II Trial Results for Ozekibart in Chondrosarcoma, Plans BLA Submission by 2026
  Stock News · 10-31
  TRANSCENTA-B (06628) Partner Inhibrx Reports Positive Phase II Trial Results for Ozekibart in Chondrosarcoma, Plans BLA Submission by 2026
- Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
  Reuters · 10-31
  Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
- Transcenta (6628) Announces Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart, Plans BLA Submission by 2026
  Bulletin Express · 10-31
  Transcenta (6628) Announces Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart, Plans BLA Submission by 2026
- TRANSCENTA-B Chairman Qian Xueming Increases Holdings by 10,000 Shares at HK$4.62 per Share
  Deep News · 09-28
  TRANSCENTA-B Chairman Qian Xueming Increases Holdings by 10,000 Shares at HK$4.62 per Share
- Board Chairman Qian Xueming Increases Holdings in TRANSCENTA-B (06628) by 10,000 Shares at Approximately HK$4.62 Per Share
  Stock News · 09-26
  Board Chairman Qian Xueming Increases Holdings in TRANSCENTA-B (06628) by 10,000 Shares at Approximately HK$4.62 Per Share
- Chairman Qian Xueming Increases Holdings in TRANSCENTA-B (06628) by 20,000 Shares at HK$4.16 Per Share
  Stock News · 09-23
  Chairman Qian Xueming Increases Holdings in TRANSCENTA-B (06628) by 20,000 Shares at HK$4.16 Per Share
- Hong Kong Stock Movement | TRANSCENTA-B (06628) Surges Over 10% in Late Trading on $1.5 Billion Innovative Drug Pipeline RWA Tokenization Partnership with IVD MEDICAL
  Stock News · 09-23
  Hong Kong Stock Movement | TRANSCENTA-B (06628) Surges Over 10% in Late Trading on $1.5 Billion Innovative Drug Pipeline RWA Tokenization Partnership with IVD MEDICAL
- Transcenta, IVD Medical to Explore RWA Tokenization of Drug Pipeline
  MT Newswires Live · 09-22
  Transcenta, IVD Medical to Explore RWA Tokenization of Drug Pipeline
- IVD MEDICAL (01931) and TRANSCENTA-B (06628) Sign Strategic Cooperation Agreement for RWA Tokenization of $1.5 Billion Innovative Drug Pipeline Assets
  Stock News · 09-22
  IVD MEDICAL (01931) and TRANSCENTA-B (06628) Sign Strategic Cooperation Agreement for RWA Tokenization of $1.5 Billion Innovative Drug Pipeline Assets
Company Profile
Company Name
TRANSCENTA-B
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.transcenta.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Transcenta Holding Ltd is a investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company also provides contract development and manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.

1D
5D
Day
Week
Month

Loading ...

High

2.300

Open

2.300

Volume%

2.82

Low

2.130

2.350

T/O Rate

0.27%

To The Moon

TRANSCENTA-B(06628)

Company Profile

Most Discussed